KR20230015965A - Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법 - Google Patents

Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법 Download PDF

Info

Publication number
KR20230015965A
KR20230015965A KR1020227045054A KR20227045054A KR20230015965A KR 20230015965 A KR20230015965 A KR 20230015965A KR 1020227045054 A KR1020227045054 A KR 1020227045054A KR 20227045054 A KR20227045054 A KR 20227045054A KR 20230015965 A KR20230015965 A KR 20230015965A
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227045054A
Other languages
English (en)
Korean (ko)
Inventor
제니퍼 디. 해밀턴
제니퍼 말로니
레다 마넨트
마르셀라 루디
Original Assignee
리제너론 파아마슈티컬스, 인크.
사노피 바이오테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크., 사노피 바이오테크놀로지 filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20230015965A publication Critical patent/KR20230015965A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020227045054A 2020-05-22 2021-05-21 Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법 Pending KR20230015965A (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063029085P 2020-05-22 2020-05-22
US63/029,085 2020-05-22
US202063066705P 2020-08-17 2020-08-17
US63/066,705 2020-08-17
US202063071264P 2020-08-27 2020-08-27
US63/071,264 2020-08-27
US202063088147P 2020-10-06 2020-10-06
US63/088,147 2020-10-06
US202063121088P 2020-12-03 2020-12-03
US63/121,088 2020-12-03
US202163144939P 2021-02-02 2021-02-02
US63/144,939 2021-02-02
EP21315068 2021-04-21
EP21315068.3 2021-04-21
PCT/US2021/033693 WO2021237110A1 (en) 2020-05-22 2021-05-21 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Publications (1)

Publication Number Publication Date
KR20230015965A true KR20230015965A (ko) 2023-01-31

Family

ID=76444669

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045054A Pending KR20230015965A (ko) 2020-05-22 2021-05-21 Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법

Country Status (11)

Country Link
US (1) US20250154267A2 (https=)
EP (1) EP4153300A1 (https=)
JP (1) JP2023527775A (https=)
KR (1) KR20230015965A (https=)
CN (1) CN115768516A (https=)
AU (1) AU2021277398A1 (https=)
BR (1) BR112022022235A2 (https=)
CA (1) CA3174431A1 (https=)
IL (1) IL298257A (https=)
MX (1) MX2022014440A (https=)
WO (1) WO2021237110A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CA3246860A1 (en) * 2022-04-26 2023-11-02 Regeneron Pharmaceuticals, Inc. TRANSCRIPTOME ANALYSIS FOR THE TREATMENT OF INFLAMMATION
KR20250037491A (ko) 2022-07-08 2025-03-17 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여에 의한 소아 호산구성 식도염을 치료하는 방법
EP4688142A1 (en) 2023-03-27 2026-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
WO2025221247A1 (en) * 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TWI682781B (zh) * 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP6871948B2 (ja) * 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
TWI728172B (zh) * 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US11053309B2 (en) * 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
IL315556A (en) * 2017-08-04 2024-11-01 Regeneron Pharma Methods for treating active eosinophilic esophagitis
CA3090832A1 (en) * 2018-02-21 2019-08-29 Adare Pharmaceuticals Us, L.P. Methods of managing eosinophilic esophagitis
JPWO2019240288A1 (ja) * 2018-06-14 2021-07-26 味の素株式会社 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도

Also Published As

Publication number Publication date
CN115768516A (zh) 2023-03-07
JP2023527775A (ja) 2023-06-30
US20250154267A2 (en) 2025-05-15
US20210363264A1 (en) 2021-11-25
EP4153300A1 (en) 2023-03-29
CA3174431A1 (en) 2021-11-25
MX2022014440A (es) 2023-02-27
AU2021277398A1 (en) 2023-02-02
IL298257A (en) 2023-01-01
WO2021237110A1 (en) 2021-11-25
BR112022022235A2 (pt) 2023-03-28

Similar Documents

Publication Publication Date Title
KR20230015965A (ko) Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
US11053309B2 (en) Methods for treating active eosinophilic esophagitis
JP2019531273A (ja) Ｉｌ−４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
JP7811933B2 (ja) 活動性好酸球性食道炎を治療する方法
RS65652B1 (sr) Postupci lečenja bolesti u kojima je dejstvo il-13 štetno pomoću antitela protiv il-13
IL323497A (en) Methods for treating eosinophilic gastroenteritis by administering an IL-4R antagonist
US20240034798A1 (en) Methods for treating eosinophilic esophagitis by administering an il-4r antagonist
RU2848340C1 (ru) Способы лечения эозинофильного эзофагита путем введения ингибитора il-4r
RU2776651C2 (ru) Способы лечения активного эозинофильного эзофагита
EA045955B1 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240507

Comment text: Request for Examination of Application